Arbutus Biopharma Stock Discussion

$Arbutus Biopharma (ABUS.US)$
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV).
When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with baseline ...

$Arbutus Biopharma (ABUS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial for chronic hepatitis B treatment.
The study evaluated the combination of imdusiran, VTP-300, and low-dose nivolumab.
Key findings show that 23% of participants receiving the triple combinati...

$Arbutus Biopharma (ABUS.US)$
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings fr...

$Arbutus Biopharma (ABUS.US)$ Trading quotes resume at 7:55 and trading at 8:00AM est

$Arbutus Biopharma (ABUS.US)$ Reuters· 1 min ago
Arbutus Biopharma Corp: Prioritizing Imdusiran Phase 2B Clinical Development. Also planning 40% reduction in workforce

$Arbutus Biopharma (ABUS.US)$ 🤔

$Arbutus Biopharma (ABUS.US)$ $Barinthus Biotherapeutics (BRNS.US)$ Arbutus Biopharma (ABUS) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' (BRNS) VTP-300 was generally safe and well-tolerated.
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
...

$Arbutus Biopharma (ABUS.US)$
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks ...

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$  Phase 2
$Supernus Pharmaceuticals (SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$  Phase 2a
$MorphoSys (MOR.US)$  Phase 2
$Nuvation Bio (NUVB.US)$  Phase 2
$ALX Oncology (ALXO.US)$  Phase 2
$BioXcel Therapeutics (BTAI.US)$  Phase 2
$Purple Biotech (PPBT.US)$  Phase 2
$Arcus Biosciences (RCUS.US)$  Phase 2
$Medicenna Therapeutics (MDNAF.US)$  Phase 2b
$Affimed NV (AFMD.US)$  Phase 2
$Barinthus Biotherapeutics (BRNS.US)$  Phase 2b...